Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company dedicated to developing life-changing therapies for patients afflicted with cancer and diabetes. The company's mission is to advance novel gene therapies by administering disease-fighting genes to provide new treatment options for large patient populations who currently have limited choices. Founded in 2009, Genprex is headquartered in Austin, Texas.

Genprex's primary oncology product candidate is REQORSA® (quaratusugene ozeplasmid), an immunogene therapy currently undergoing evaluation in multiple clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This therapy leverages the proprietary, non-viral ONCOPREX® Nanoparticle Delivery System. In its diabetes pipeline, Genprex is developing GPX-002, a preclinical gene therapy candidate designed to stabilize glucose levels and reduce insulin requirements in both Type 1 and Type 2 diabetes by delivering Pdx1 and MafA genes to the pancreas.

Genprex has received multiple FDA Fast Track Designations for its lung cancer clinical programs, with its SCLC program also holding an FDA Orphan Drug Designation. Recent developments in early 2026 include the granting of patents in Israel, Japan, and the EU for REQORSA in combination with immunotherapies for cancer treatment. Additionally, positive preclinical data for both REQORSA and the diabetes gene therapy candidate GPX-002 have been presented at scientific meetings. Ryan Confer serves as the President and CEO of the company. Genprex, Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol GNPX.